BioMarin Pharmaceuticals BMRN PALYNZIQ — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's palynziq — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's PALYNZIQ — total revenues?
- BioMarin Pharmaceuticals (BMRN) reported PALYNZIQ — total revenues of $89.56M in Q1 2026.
- How has BioMarin Pharmaceuticals's PALYNZIQ — total revenues changed year-over-year?
- BioMarin Pharmaceuticals's PALYNZIQ — total revenues decreased by 4.0% year-over-year, from $93.27M to $89.56M.
- What is the long-term trend for BioMarin Pharmaceuticals's PALYNZIQ — total revenues?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's PALYNZIQ — total revenues has grown at a 16.2% compound annual growth rate (CAGR), from $237.47M to $433.31M.
- What does PALYNZIQ — total revenues mean?
- The total gross sales revenue generated by a specific pharmaceutical product.
- How do you interpret PALYNZIQ — total revenues?
- An increase indicates growing market penetration, successful patient acquisition, or expanded clinical adoption, while a decrease may signal increased competition, patent expiration, or market saturation.
- How does PALYNZIQ — total revenues compare across companies?
- Comparable to product-specific net sales reported by other biopharmaceutical companies, often benchmarked against therapeutic area peers.